Abstract
Elderly patients represent at least 40% of head and neck squamous cell carcinoma (HNSCC). These patients often receive inadequate treatment, either exceeding their tolerance capability or exposing them to a lesser chance of cure because of undertreatment. Customizing treatment to the individual patient is the key for avoiding such pitfalls. This paper analyses the literature on optimal management of elderly patients with HNSCC, from the diagnostic procedures with a comprehensive geriatric assessment (CGA) of co-morbidities to the specific recommendations for surgery, radiotherapy, and chemotherapy.
Keywords
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Horner MJ, Ries LAG, Krapcho M, Neyman N, Aminou R, Howlader N, et al., editors. SEER Cancer Statistics Review, 1975–2006. Bethesda: National Cancer Institute; 2008.
Pignon T, Horiot JC, Van Den Bogaert W, Van Glabbeke M, Scalliet P. No age limit for radical radiotherapy in head and neck tumours. Eur J Cancer. 1996;32(12):2075–81.
Horiot JC. Revisiting the concept of age limit in radiotherapy research protocols. Proceedings of the 5th meeting of the International Society of Geriatric Oncology; San Francisco; 2004. p. 91–93.
Horiot JC. Radiation therapy and the geriatric oncology patient. J Clin Oncol. 2007;25(14):1930–5.
Metges JP, Eschwège F, de Crevoisier R, et al. Radiotherapy in head and neck cancer in the elderly: a challenge. Crit Rev Oncol Hematol. 2000;34:195–203.
Schofield CP, Sykes AJ, Slevin NJ, et al. Radiotherapy for head and neck cancer in elderly patients. Radiother Oncol. 2003;69:37–42.
Zachariah B, Balducci L, Verkattaramanabalaji GV, et al. Radiotherapy for cancers aged 80 and older. A study of effectiveness and side effects. Int J Radiat Oncol Biol Phys. 1997;39:1125–9.
Italiano A, Ortholan C, Dassonville O, et al. Head and neck squamous cell carcinoma in patients aged > or = 80 years: patterns of care and survival. Cancer. 2008;113:3160–8.
Ortholan C, Lusinchi A, Italiano A, et al. Oral cavity squamous cell carcinoma in 260 patients aged 80 years or more. Radiother Oncol. 2009;93:516–23.
Reizenstein JA, Bergström SN, Holmberg L, et al. Impact of age at diagnosis on prognosis and treatment in laryngeal cancer. Head Neck. 2009;32:1062–8.
Extermann M. Studies of comprehensive geriatric assessment in patients with cancer. Cancer Control. 2003;10:463–8.
Extermann M, Hurria A. Comprehensive geriatric assessment for older patients with cancer. J Clin Oncol. 2007;25:1824–31.
Repetto L, Fratino L, Audisio RA, et al. Comprehensive geriatric assessment adds information to Eastern Cooperative Oncology Group performance status in elderly cancer patients: an Italian Group for Geriatric Oncology Study. J Clin Oncol. 2002;20:494–502.
Extermann M, Aapro M, Bernabei R, et al. Use of comprehensive geriatric assessment in older cancer patients: recommendations from the task force on CGA of the International Society of Geriatric Oncology (SIOG). Crit Rev Oncol Hematol. 2005;55:241–52.
Rodin MB, Mobile SG. A practical approach to geriatric assessment in patients with cancer. J Clin Oncol. 2007;25:1936–44.
Sanabria A, Carvalho AL, Vartanian JG, et al. Comorbidity is a prognostic factor in elderly patients with head and neck cancer. Ann Surg Oncol. 2007;14:1449–57.
Tran M, Raynard B, Bataillard A, Duguet A, Garabige V, Lallemand Y, et al. Standards, Options and Recommendations 2005 for a good practice in enteral nutrition in oncology (summary report). Bull Cancer. 2006;93:715–22.
Horiot JC, Schraub S, Bone MC, et al. Dental preservation in patients irradiated for head and neck tumours: a 10 year experience with topical fluoride and a randomized trial between two fluoridation methods. Radiother Oncol. 1983;1:77–82.
Sanabria A, Carvalho AL, Melo R, et al. Predictive factors for complications in elderly patients who underwent oncologic surgery. Head Neck. 2008;30(2):170–7.
Pompei S, Tedesco M, Pozzi M, et al. Age as a risk factor in cervico-facial reconstruction. J Exp Clin Cancer Res. 1999;18:209–12.
Ashley J, Duggan M, Sutcliffe N. Speech, language and swallowing disorders in older adult. Clin Geriartr Med. 2006;22:291–310.
Werner JA, Dunne AA, Folz BJ, et al. Transoral laser microsurgery in carcinomas of the oral cavity, pharynx and larynx. Cancer Control. 2002;9:379–86.
Audisio RA, Bozzetti F, Gennari R, et al. The surgical management of elderly cancer patients: recommendations of the SIOG surgical task force. Eur J Cancer. 2004;40:926–38.
Dubec JJ, Munk PL, Tsang V, et al. Carotid artery stenosis in patients who have undergone radiotherapy for head and neck malignancies. Br J Radiol. 1998;71:872–5.
Brown PD, Foote RL, McLaughlin MP, et al. A historical prospective cohort study of carotid artery stenosis after radiotherapy for head and neck malignancies. Int J Radiat Oncol Biol Phys. 2005;63:1361–7.
Falandry C, Tartouki K, Mornex F, et al. Is geriatric assessment adapted to radiotherapy? Cancer Radiothér. 2008;12:541–7.
van Rij CM, Oughlane-Heemsbergen WD, Ackerstaff AH, Lamers EA, Balm AJM, Rasch CRN. Parotid gland sparing IMRT for head and neck cancer improves xerostomia related quality of life. Radiat Oncol. 2008;3:41.
Pignon JP, le Maître A, Bouhris J, et al. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update. Int J Radiat Oncol Biol Phys. 2007;69(2 Suppl):S112–4.
Bernier J. Current state-of-the-art for concurrent chemo-radiation. Semin Radiat Oncol. 2009;19:3–10.
Lefebvre JL, Chevalier D, Luboinski B, et al. Larynx preservation in pyriform sinus cancer: preliminary results of a European Organization for Research and Treatment of Cancer phase III trial. EORTC Head and Neck Cancer Cooperative Group. J Natl Cancer Inst. 1996;88(13):890–9.
Lefebvre JL, Rolland F, Tesselaar M, et al. Phase 3 randomized trial on larynx preservation comparing sequential vs. alternating chemotherapy and radiotherapy. J Natl Cancer Inst. 2009;101(3):142–52.
Vermorken JB, Remenar E, van Herpen C, et al. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med. 2007;357(17):1695–704.
Fliser D. Assessment of renal function in elderly patients. Curr Opin Nephrol Hypertens. 2008;17:604–8.
Adelstein DJ, Ly Y, Adams JL, et al. An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with resectable squamous cell head and neck cancer. J Clin Oncol. 2003;21:92–8.
Cooper JS, Pajak TF, Forastiere AA, et al. Postoperative concurrent radiotherapy and chemotherapy for high risk squamous cell carcinoma of the head and neck. N Engl J Med. 2004;350:1937–44.
Calais G, Alfonsi M, Bardet E, et al. Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma. J Natl Cancer Inst. 1999;91(24):2081–6.
Machtay M, Moughan J, Trotti A, et al. Factors associated with severe late toxicity after concurrent chemoradiation for locally advanced head and neck cancer: an RTOG analysis. J Clin Oncol. 2008;26:3582–9.
Lokich J, Anderson N. Carboplatin versus cisplatin in solid tumors: an analysis of the literature. Ann Oncol. 1998;9:13–21.
Wildiers H. Mastering chemotherapy dose reductions in elderly cancer patients. Eur J Cancer. 2007;43:2235–41.
Lichtman SM, Hollis D, Miller AA, et al. Prospective evaluation of the patient age and paclitaxel clinical pharmacology: cancer and leukemia group B (CALGB 9762). J Clin Oncol. 2006;24:1846–704.
Choi YJ, Chung J, Shin HJ, Cho GJ, et al. Induction chemotherapy of docetaxel and Cisplatin for the elderly patients with squamous cell carcinoma of the head and neck. Cancer Res Treat. 2007;39(1):1–5.
Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 2006;354:567–78.
Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol. 2010;11:21–8.
Athanassios A. EGFR antisense DNA added to cetuximab and radiotherapy for head and neck cancer. Grant 1R21CA130241-01A1 from National Cancer Institute.
Bernier J. Cetuximab: a standard approach to the first-line treatment of recurrent and/or metastatic and locally advanced squamous cell carcinoma of the head and neck. Oncol Rev. 2009;3:247–56.
Vermorken JB, Mesia R, Rivera F, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med. 2008;359:1116–27.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2011 Springer Science+Business Media, LLC
About this chapter
Cite this chapter
Horiot, JC., Aapro, M.S. (2011). Treatment of the Elderly Head and Neck Cancer Patient. In: Bernier, J. (eds) Head and Neck Cancer. Springer, New York, NY. https://doi.org/10.1007/978-1-4419-9464-6_41
Download citation
DOI: https://doi.org/10.1007/978-1-4419-9464-6_41
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4419-9463-9
Online ISBN: 978-1-4419-9464-6
eBook Packages: MedicineMedicine (R0)